Interferon (IFN) production by spleen cells from normal mice, mice acutely infected with Semliki Forest virus (SFV) or mice immune to SFV was measured after stimulation in vitro with either infectious or inactivated SFV. All three classes of spleen cells made IFN-alpha beta in response to infectious SFV. Spleen cells taken from mice late, but not early, after infection, or from immune mice, made IFN-gamma in response to inactivated SFV. Amounts of INF-gamma and IFN-alpha beta were similar. Normal spleen cells made no IFN (of any type) in response to inactivated SFV. The cell type producing IFN-alpha beta appeared to be the macrophage, whilst both T-lymphocytes and macrophages were necessary for IFN-gamma production. During the acute infection, the ability of spleen cells to lyse both virus-infected and uninfected target cells arose earlier than the ability to produce IFN-gamma. However, cytotoxicity towards uninfected cells fell to near background levels by day 7, whilst cytotoxicity towards infected targets remained high at that time, when IFN-gamma production was at its peak. IFN-gamma production is therefore temporally associated with cytotoxicity specifically directed against virus-infected targets, and the ability to produce IFN-gamma is a late response to SFV infection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1099/0022-1317-65-5-955 | DOI Listing |
Drug Deliv Transl Res
January 2025
Kinimmune, Inc. St. Louis, 63141, Missouri, USA.
PD-L1/PD-1 checkpoint inhibitors (CPIs) are mainstream agents for cancer immunotherapy, but the prognosis is unsatisfactory in solid tumor patients lacking preexisting T-cell reactivity. Adjunct therapy strategies including the intratumoral administration of immunostimulants aim to address this limitation. CpG oligodeoxynucleotides (ODNs), TLR9 agonists that can potentiate adaptive immunity, have been widely investigated to tackle PD-L1/PD-1 resistance, but clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure.
View Article and Find Full Text PDFAngew Chem Int Ed Engl
January 2025
University of Science and Technology of China School of Biomedical Engineering, Department of Polymer Science and Engineering, 96 Jinzhai Road, 230026, Hefei, CHINA.
Lipid nanoparticles (LNPs) based messenger RNA (mRNA) therapeutics hold immense promise for treating a wide array of diseases, while their nonhepatic organs targeting and insufficient endosomal escape efficiency remain challenges. For LNPs, polyethylene glycol (PEG) lipids have a crucial role in stabilizing them in aqueous medium, but they severely hinder cellular uptake and reduce transfection efficiency. In this study, we designed ultrasound (US)-assisted fluorinated PEGylated LNPs (F-LNPs) to enhance spleen-targeted mRNA delivery and transfection.
View Article and Find Full Text PDFCerebral malaria (CM) is a severe complication of Plasmodium falciparum infection, with resistance to antimalarial drugs, including artemisinin-based combination therapies(ACTs), posing a significant threat. CD4+ naive cells expressing CCR7 are known to play a protective role, as they readily migrate to secondary lymphoid tissues activated by CCL19 chemokines. In an effort to address this challenge, we investigated the impact of Annona muricata, an herbaceous and immunomodulatory plant, on CCL19 concentration.
View Article and Find Full Text PDFInfectious diseases pose significant challenges to Norwegian Atlantic salmon aquaculture. Vaccines are critical for disease prevention; however, a deeper understanding of the immune system is essential to improve vaccine efficacy. Immunoglobulin M (IgM) is the main antibody involved in the systemic immune response of teleosts, including Atlantic salmon.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Surgical Oncology, Guthrie Robert Packer Hospital, Sayre, Pennsylvania, USA.
A splenic inflammatory pseudotumour (IPT) is a rare condition in which inflammatory cells and non-cancerous specialised cells known as myofibroblasts abnormally replicate in the spleen. Patients with IPT may experience symptoms like abdominal pain, fever and weight loss, making it difficult to distinguish from processes like cancer. As a result, diagnosing IPT often requires imaging studies and microscopic examination.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!